HCW Biologics S-1 flags new Nasdaq market-value rule and SEC stay on its approval

HCW Biologics Inc. filed an S-1 registration statement dated August 20, 2026, covering resale of up to 1,237,364 shares of common stock tied to its July 29, 2026 private placement. The company issued 618,682 units combining common stock or pre-funded warrants with rights to common warrants, for aggregate gross proceeds of approximately $1.6 million¹. CEO Hing C. Wong, Chairman Scott Garrett, and SVP Lee Flowers participated in the July 2026 PIPE Transaction on the same terms and conditions as the other investors¹. The common warrants will be issued only following stockholder approval under Nasdaq Listing Rule 5635(d), will be exercisable at $2.585 per share and will expire five and one-half years from issuance¹.

The filing adds new detail on Nasdaq's evolving listing standards. Beyond the bid-price compliance issues previously disclosed, the company noted that Nasdaq has proposed a new continued listing requirement based on Market Value of Listed Securities, or MVLS¹. Regulators moved to advance that rule and then paused it: the SEC approved Nasdaq's proposed rule change requiring Nasdaq Capital Market companies to maintain an MVLS of at least $5 million¹, with a company falling short for 30 consecutive business days facing an immediate delisting determination with no chance to submit a compliance plan or receive a cure period¹. Days later, the SEC temporarily stayed the effectiveness of its approval order after receiving notices of intention to petition for review of the delegated action¹, leaving the implementation, timing and ultimate status of the proposed MVLS requirement uncertain¹.

On the clinical side, HCW9302 is being evaluated in alopecia areata patients under trial NCT07049328, with a June 16, 2026 preliminary readout from the first two dose cohorts showing the drug was generally well tolerated with no dose-limiting toxicities and preliminary signs of clinical activity in the second cohort; enrollment and dose escalation continue, with a full Phase 1 readout expected in the fourth quarter of 2026¹. The company also disclosed an August 14, 2026 restatement of first-quarter financials tied to an EPS calculation error.